Lifecore Biomedical (FRA:LDE) Total Liabilities: €219.66 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
58 GF Score
Price €3.98
GF Value €5.64
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Total Liabilities?

Lifecore Biomedical FRA:LDE -2.45% 58 Total Liabilities is €219.66 Mil as of Mar. 2026. GuruFocus rates FRA:LDE with a GF Score™ of 58/100 and a GF Value™ of €5.64 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Lifecore Biomedical's Total Liabilities for the quarter that ended in Mar. 2026 was €219.66 Mil.

Lifecore Biomedical's quarterly Total Liabilities increased from Sep. 2025 (€209.37 Mil) to Dec. 2025 (€210.41 Mil) and increased from Dec. 2025 (€210.41 Mil) to Mar. 2026 (€219.66 Mil).

Lifecore Biomedical's annual Total Liabilities declined from May. 2023 (€237.15 Mil) to May. 2024 (€224.45 Mil) and declined from May. 2024 (€224.45 Mil) to May. 2025 (€211.11 Mil).

Lifecore Biomedical Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Total Liabilities Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 247.02 176.79 237.15 224.45 211.11

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 226.05 211.11 209.37 210.41 219.66
FRA:LDE
58GF Score
Lifecore Biomedical Inc FRA:LDE
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lifecore Biomedical's Total Liabilities for the fiscal year that ended in May. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=26.768+(112.648+71.695
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=211.11

Total Liabilities=Total Assets (A: May. 2025 )-Total Equity (A: May. 2025 )
=212.296-1.185
=211.11

Lifecore Biomedical's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.73+(127.829+74.097
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=219.66

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=195.057--24.599
=219.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €219.66 Mil mean?
Lifecore Biomedical (FRA:LDE) has a Total Liabilities of €219.66 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Total Liabilities too high?
Lifecore Biomedical's current Total Liabilities is €219.66 Mil. Overall, Lifecore Biomedical has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Total Liabilities compare to ANIK and DERM?
Lifecore Biomedical's Total Liabilities of €219.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lifecore Biomedical and its competitors. Lifecore Biomedical's current Total Liabilities is €219.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (FRA:LDE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.64, compared to a current price of €3.98 — trading 29.4% below its estimated fair value. The current Total Liabilities is €219.66 Mil. Lifecore Biomedical's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current Total Liabilities is €219.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €3.98 is trading 29.4% below its estimated GF Value™ of €5.64. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for FRA:LDE:

  • Total Liabilities: €219.66 Mil
  • GF Value™: €5.64 vs. price of €3.98 (29.4% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
58GF Score

Get the complete analysis for FRA:LDE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.98
Price
€5.64
GF Value